Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway

Figure 6

Schematic representation of the antitumor mechanism of the lenvatinib-alisertib combination in HCC. Alisertib, a novel AURKA inhibitor that affects the DNA damage pathway and its downstream signaling, induces hepatocellular carcinoma cell death together with lenvatinib.